Repurposing Metformin as Therapy for Prostate Cancer within the STAMPEDE Trial Platform

Publikation

Repurposing Metformin as Therapy for Prostate Cancer within the STAMPEDE Trial Platform

Wissenschaftlicher Artikel/Review - 19.07.2016

Gillessen Sommer Silke, Gilson Clare, James Nick, Adler Amanda, Sydes Matthew R, Clarke Noel

Zitation

Gillessen Sommer S, Gilson C, James N, Adler A, Sydes M, Clarke N. Repurposing Metformin as Therapy for Prostate Cancer within the STAMPEDE Trial Platform. Eur Urol 2016; 70:906-908.

Art

Wissenschaftlicher Artikel/Review (Englisch)

Zeitschrift

Eur Urol 2016; 70

Veröffentlichungsdatum

19.07.2016

eISSN (Online)

1873-7560

Seiten

906-908

Kurzbeschreibung/Zielsetzung

UNASSIGNED
Metformin is a safe, well-tolerated, inexpensive treatment that can be given in addition to current standard-of-care therapies for prostate cancer. Its use might mitigate the deleterious side effects of castration and exert an additional anticancer effect. It will be incorporated in the STAMPEDE trial platform in summer 2016. This will test its true utility as a repurposed treatment for men with high-risk locally advanced or metastatic prostate cancer at first presentation.